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An awareness of the importance of nutritional status in hospital settings began more than 40
years ago. Much has been learned since and has altered care. For the past 40 years several
large studies have shown that cancer patients are amongst the most malnourished of all pa-
tient groups. Recently, the use of gold-standard methods of body composition assessment,
including computed tomography, has facilitated the understanding of the true prevalence
of cancer cachexia (CC). CC remains a devastating syndrome affecting 50–80 % of cancer
patients and it is responsible for the death of at least 20 %. The aetiology is multifactorial
and complex; driven by pro-inflammatory cytokines and specific tumour-derived factors,
which initiate an energy-intensive acute phase protein response and drive the loss of skeletal
muscle even in the presence of adequate food intake and insulin. The most clinically relevant
phenotypic feature of CC is muscle loss (sarcopenia), as this relates to asthenia, fatigue,
impaired physical function, reduced tolerance to treatments, impaired quality of life and
reduced survival. Sarcopenia is present in 20–70 % depending on the tumour type. There
is mounting evidence that sarcopenia increases the risk of toxicity to many chemotherapy
drugs. However, identification of patients with muscle loss has become increasingly difficult
as 40–60 % of cancer patients are overweight or obese, even in the setting of metastatic dis-
ease. Further challenges exist in trying to reverse CC and sarcopenia. Future clinical trials
investigating dose reductions in sarcopenic patients and dose-escalating studies based on
pre-treatment body composition assessment have the potential to alter cancer treatment
paradigms.
Cancer: Cachexia: Sarcopenia: Quality of life: Malnutrition: Survival
Over 40 years ago Charles Butterworth penned the now
infamous ‘Skeleton in the Hospital Closet’ paper which
highlighted the ‘downright neglect of nutritional health’
in hospitals in the USA(1). He argued that ‘one of the lar-
gest pockets of unrecognised malnutrition in the USA
and Canada was not in rural slums or urban ghettos,
but in the private rooms of big city hospitals’.
Furthermore, he adds that ‘when a sick person commits
himself to the total, unquestioning care of his doctor, his
nutritional health at least should be assured. . .and it
becomes imperative to ensure that preventable malnutri-
tion does not contribute to mortality, morbidity and pro-
longed hospital stay’.
Shortly after this paper was published, articles began to
appear in peer-reviewed journals highlighting the enor-
mous problem of malnutrition in cancer patients. In a
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classic study by Dewys et al.(2) on 3047 patients with dif-
ferent tumour types, moderate-to-severe weight loss was
reported in 30–70 %. The greatest incidence of weight
loss was seen in patients with solid tumours, e.g. gastric,
pancreatic, lung, colorectal and head and neck. Within
each tumour type, survival times were shorter for patients
who had experienced weight loss and there was a trend to-
wards decreased chemotherapy response rates(2).
Almost 30 years later in 2009, Bozzetti et al.(3)
reported on the nutritional status of 1000 oncology out-
patients reporting that 40 % had lost more than 10 % of
their body weight and over 50 % had anorexia. The mean
weight loss in patients with solid tumours of the upper
gut was 15 %. When cancer patients are compared with
other hospital patients they come out as amongst the
most malnourished(3). In a recent study by Tangvik
et al.(4) which screened 3279 hospital patients, 49 % of
cancer patients assessed were at nutritional risk, second
only to those with acute infections. In this study, the
highest number of patients at nutritional risk had a
BMI in the normal or overweight category and were
aged 60–80 years(4). The largest study to date of 8160
cancer patients from Canada and Europe with locally
advanced or metastatic disease reported that 73 % experi-
enced involuntary weight loss and that BMI and percent-
age weight loss predicted survival independent of disease
site, stage or performance score(5).
Aetiology
Nutritional deterioration has unfortunately become an
accepted part of the pathogenesis of cancer and its treat-
ment. The degree of malnutrition that occurs is affected
by cancer type, stage and therapy modality; however,
the aetiology of cancer-induced weight loss is multifactor-
ial and complex. Changes in nutrition status can occur at
any point in the timeline of cancer diagnosis, treatment or
support(6). These changes may occur as a result of meta-
bolic changes, mechanical blockages or abnormalities,
side effects of treatment or psychosocial issues.
Insufficient oral intake
Several factors may directly lead to diminished food in-
take and thereby insufficient energy intake, e.g. dyspha-
gia, nausea, xerostomia and changes in taste and
smell(7). Other factors may have an indirect influence on
energy intake by affecting appetite and the drive to eat,
e.g. pain, fatigue and psychological problems(8). Studies
have suggested that a high prevalence of taste changes
are associated with poor intakes in advanced cancer and
that individuals reporting taste changes may ingest as lit-
tle as 3765·6–4602·4 kJ/d (900–1100 kcal/d)(9) with other
studies reporting energy deficits of up to 230 120 kJ (55 000
calories) during chemoradiotherapy in head and neck
cancers(10). A wide variation in energy intake has been
reported in cancer ranging from 16·74 to 221·75 kJ/kg
per d (4 to 53 kcal/kg per d)(8).
Tumour-related mechanisms
Tumour-related mechanisms include obstruction of the
gastrointestinal tract causing dysphagia or odynophagia,
as seen in oesophageal and head and neck cancers.
Weight loss can be attributed to the physiologic abnor-
malities associated with the tumour, such as malabsorp-
tion, vomiting, diarrhoea, anorexia or the side effects of
anti-cancer treatment, including chemotherapy, radio-
therapy and surgery(11–13). Oral and gastrointestinal
symptoms have early effects on changes in weight with-
out regard to nutrition status and treatment modalities.
Patients with weight loss have also been shown to have
more depression, abdominal fullness, taste changes,
vomiting, dry mouth, dysphagia or loss of appetite(7).
Host response to tumour
A variety of metabolic and endocrine changes, and acti-
vation of catabolic pathways also account for weight
loss, which is typically greater than would be expected
from the prevailing level of oral intake(7).
Pro-inflammatory cytokines (secreted by either immune
cells or tumours) play a central role in mediating the
metabolic, physiologic and behavioural features of
cancer-induced weight loss. They are key signals for lip-
olysis and proteolysis. Cytokines have three major
effects: (1) altering macronutrient metabolism, (2)
depressing appetite and (3) initiation of an acute phase
protein response. This acute phase protein response is
energy-intensive with high requirements for essential
amino acids. The need for amino acids drives the loss
of muscle. Along with the acute phase protein response,
changes in intermediary metabolism also occur, most
notably, in protein metabolism. Anorexia results from
pro-inflammatory cytokine activity and has both central
and peripheral aspects. The central effect is at the level of
the hypothalamic nuclei, which control feeding beha-
viours. Mediators such as corticotropin-releasing hor-
mone, serotonin or leptin may be directly or indirectly
involved in producing anorexia.
In addition, inflammatory cytokines directly induce
signalling pathways that up-regulate enzymes inducing
muscle protein turnover. The pathway most involved in
muscle wasting is protein degredation that is mediated
by the activation of the ubiquitin-dependent proteasome
pathway. Additionally there are abnormalities in protein
synthesis and degredation and amino acid metabolism
along with increased apoptosis and an impaired capacity
for regeneration(14).
Skeletal muscle loss is accompanied by a profound loss
of white adipose tissue due to a variety of factors.
Lipid-mobilising factor is produced by cachexia-inducing
tumours and is involved in the degradation of adipose tis-
sue, with increased oxidation of the released fatty acids
through an induction of uncoupling protein expres-
sion(15). In addition, there is an increase in lipolytic activ-
ity through activation of hormone-sensitive lipase; a
decreased anti-lipolytic effect of insulin on adipocytes;
and an important decrease in lipoprotein lipase activ-
ity(14). Consequently lipid uptake is severely hampered.
Also de novo lipogenesis in adipose tissue is also
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Table 1. Sarcopenia, weight loss and cachexia; predictors of reduced survival in cancer
Reference Cancer type
Predictor of reduced









Weight loss ≥10 %, low food intake ≤6276
kJ/d (1500 kcal/d), and systemic
inflammation (CRP≥ 10 mg/l)






Weight loss 150 Median: 406 d Weight loss was defined as any degree of
weight loss






Sarcopenic obesity 250 Until death SMI at L3, <55·4 cm2/m2 for males and <38·9
cm2/m2 females measured by CT
HR 4·2 (95 % CI 2·4, 7·2) 0·0001
Tan et al.(102) Pancreatic Sarcopenic
overweight/obese
62 Until death or
censored date
SMI at L3, ≤52·4 cm2/m2 for men and ≤38·5
cm2/m2 for women measured by CT







SMI at L3, <43·75 cm2/m2 for males and
<41·1 cm2/m2 for females measured by CT
HR 2·53 (95 % CI 1·60, 4·01) <0·001
Villasenor
et al.(103)
Breast Sarcopenic 471 Median:
9·2 years
appendicular lean mass index <5·45 kg/m2
for females measured by DXA
HR 1·95 (95 % CI 0·87, 4·35) NS
Peng et al.(37) Pancreatic Sarcopenia 557 3 years Total psoas area <492 mm2/m2 for men and
<362 mm2/m2 for females measured by CT
HR 1·63 (95 % CI 1·28, 2·07) <0·001
Martin
et al.(42)






SMI at L3, <43 cm2/m2 for men (BMI≤ 24·9
kg/m2) and <53 cm2/m2 for overweight/
obese men (BMI > 25 kg/m2), <41 cm2/m2
for women; muscle attenuation <41HU for
men and women (BMI≤ 24·9 kg/m2),
<33HU for overweight/obese men (BMI >
25 kg/m2); weight loss ≥8 % measured by
CT
Independent of BMI, patients with all three
features (weight loss, low muscle
attenuation and low muscle index) survived
8·4 months (95 % CI 6·5, 10·3) v. 28·4
months (95 % CI 24·2, 32·6) in patients with











SMI at L3, ≤52·4 cm2/m2 for men and ≤38·9
cm2/m2 for women measured by CT
HR 3·19 (95 % CI 1·28, 7·96) 0·013
Psutka
et al.(105)
Bladder Sarcopenia 205 6·7 years SMI at L3, < 55 cm2 /m2 for men and <39
cm2/m2 for women measured by CT





Sarcopenia 93 13 months SMI at L3, <43 cm2/m2 for men (BMI < 25
cm2/m2), <53 cm2/m2 for overweight/obese
men & <41 cm2/m2 for women measured by
CT
HR 2·13 (95 % CI 1·15, 3·92) 0·016
Miyamoto
et al.(49)
Colorectal Sarcopenia 220 Median:
41·4 months
SMI at L3, those in the lowest quartiles for
SMI at L3, for men: 32·6–49·5 cm2/m2; for
women 15·6–42·1 cm2/m2





Weight loss 8160 Median:
41·3 months
A robust grading system was developed
incorporating the independent prognostic
significance of both BMI and % weight loss
On average, there was a 4·9-fold difference in
median survival between grade 0 (weight
stable patients with BMI≥ 25·0 kg/m2) and
grade 4 (lowest BMI and highest % weight
loss) (20·9 months v. 4·3 months,
respectively)
<0·001
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reduced(14,16). There are also recent data to suggest that
white adipose tissue cells undergo a browning process
and brown adipose tissue is associated with increased ex-
pression of uncoupling protein 1, which switches the use
of mitochondrial electron transport from ATP synthesis
to thermogenesis, resulting in increased lipid mobilisa-
tion and energy expenditure(14). Adipose tissue also infil-
trates muscle resulting in reduced muscle density(17).
Energy expenditure and physical activity
The resting energy expenditure (REE) in cancer patients
is determined by the type of tumour. REE can be un-
changed, increased or decreased in relation to the pre-
dicted energy expenditure(18–20). In about 25 % of
patients with active cancer, REE measured by the gold
standard method, indirect calorimetry, is more than
10 % higher, and in another 25 % it is more than 10 %
lower than predicted energy expenditure(21). REE has
been shown to be significantly elevated in patients with
an acute phase response(22).
Although REE may be elevated in cancer patients, the
total energy expenditure is often decreased through re-
duction in the physical activity level (PAL) and it has
been reported that that weight-losing cancer patients re-
duce the magnitude of their energy deficit by a reduction
in PAL. Healthy sedentary adults have a PAL between
1·4 and 1·5(23). In a study of hypermetabolic, cachectic
pancreatic cancer patients, it was shown that the mea-
sured mean PAL was much lower (mean 1·24) than
that recorded in healthy adults of similar age (mean
1·62)(24). This level of physical activity is comparable
with that observed in spinal cord injury patients living
at home(25) or that observed in cerebral palsy (mean
PAL 1·23)(26). Levels of physical activity as low as this
may exacerbate muscle wasting(27,28) and it is well under-
stood in any individual, that a lack of physical activity
will cause deconditioning and deterioration in muscle
mass(29) which in turn impacts the ability to exercise.
This vicious cycle leads to progressive decline in physical
activity and of muscle mass.
Cancer cachexia
The wasting in cancer is often termed cancer cachexia
(CC) and over the last few years several definitions of
CC have emerged but they all share two common fea-
tures: involuntary weight loss of muscle (and fat) and
inflammation. Debate continues in the scientific literature
surrounding its best definition and classification. Earlier
papers described CC as ‘a wasting syndrome involving
loss of muscle and fat directly caused by tumour factors,
or indirectly caused by an aberrant host response to tu-
mour presence’(30) but more recent definitions describe
it as ‘a complex metabolic syndrome associated with
underlying illness and characterised by loss of muscle
with or without loss of fat mass’(31). In addition to muscle
and adipose tissue, other organs are affected by the cach-
ectic process. Abnormalities in heart function, alterations
in liver protein synthesis, changes in hypothalamic med-
iators and activation of brown adipose tissue are also
involved in the cachectic syndrome(14). Therefore tissues
and organs such as adipose tissue, brain, liver, gut and
heart are all directly involved in the cachectic process.
In 2011, a consensus definition of CC was published
by Fearon et al.(32) which proposed new criteria for diag-
nosing CC. Briefly this definition requires any one of the
following criteria to be met: (1) involuntary weight loss
>5 % over the last 6 months in the absence of simple star-
vation; (2) weight loss >2 % with a BMI < 20 kg/m2; (3)
weight loss >2 % with an appendicular skeletal muscle
index consistent with sarcopenia as measured by
dual-energy X-ray absorptiometry (DXA; males < 7·26
kg/m2 and females < 5·45 kg/m2).
It is important to recognise that cachexia actually
represents a spectrum of conditions. The first stage is
‘precachexia’. Here, cancer cells release substances that
initiate inflammatory actions, and the body’s immune
cells are mounting a response to the presence of cancer
cells. Patients may first notice weight loss, sometimes
even before the cancer diagnosis has been made. The
‘cachexia syndrome’ is characterised by weight loss in
combination with evidence of systemic inflammation
and reduced food intake. People with ‘advanced/refrac-
tory cachexia’ have depletion of fat reserves, severe mus-
cle wasting and immunocompromise, and they are likely
to die primarily as a result of these issues(32).
Whether or not a patient progresses down the pathway
of worsening cachexia depends on the success of treating
the primary disease and on addressing cachexia as well.
Not all patients will progress down this spectrum to
full cachexia. Some will die of their primary disease be-
fore they develop advanced cachexia, others will stabilise
as a result of treatment of their primary disease. Such
heterogeneity makes it difficult to target prophylactic
therapy successfully. Prophylaxis would be best initiated
in the precachexia phase yet there are few robust predic-
tors to guide such a strategy.
Malnutrition, cancer cachexia and survival
If left untreated, tumour-related weight loss will progres-
sively worsen. Such progression will negatively impact
patient outcomes, particularly survival. There is a vast
array of published studies showing reduced survival in
weight-losing cancer patients and in those with cachexia.
Studies have consistently demonstrated that the progno-
sis for cancer patients with weight loss is worse than that
for weight-stable patients(33–36). Table 1 summarises the
available evidence for reduced survival in a variety of
cancers which report hazard ratios of death ranging
from 1·63 to 4·2(37,38). A recent large paper by Martin
et al.(5) on 8160 cancer patients developed a robust grad-
ing system which could predict survival and was based on
percentage weight loss and BMI. This research showed
that weight-stable patients with BMI > 25 kg/m2 had
the longest survival and percentage weight loss values
associated with lower BMI categories were related to
shorter survival. This study demonstrated that the loss
of the ability to maintain weight (even a weight loss of
2·4 %) is significantly related to reduced survival and
those cancer patients with the lowest BMI and highest
level of weight loss experienced survival rates consistent
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with Common Terminology Criteria for Adverse Events
grade 4 which is consistent with a life-limiting toxic side
effect from chemotherapy(5).
Overweight and obesity in cancer
There is now convincing evidence that a substantial pro-
portion of cancers are attributable to obesity. Indeed the
World Cancer Research Fund(39) estimates that between
15 and 45 % of cancers are directly related to obesity.
Despite the fact that the majority of cancer patients pre-
sent with involuntary weight loss at the time of diagno-
sis(5), in the era of obesity cancer patients may not look
malnourished and many in fact are overweight or obese
making the identification of ‘at risk’ patients harder for
medical teams caring for them. Recent studies have
reported that between 40 and 60 % of cancer patients
are overweight or obese, even in the setting of metastatic
disease(5,40–42) (see Table 2). As the most clinically rele-
vant phenotypic feature of CC is muscle loss, identifying
those with muscle loss becomes a huge challenge in over-
weight and obese patients as the loss of muscle is masked
by excessive adiposity.
Sarcopenia
Sarcopenia comes from the Greek ‘sarx’ for flesh, ‘penia’
for loss and was first defined by Evans et al. in 1993(43),
as ‘the age-related loss in skeletal muscle mass, which
results in decreased strength and aerobic capacity and
thus functional capacity’. Today more commonly it is
defined as having an appendicular skeletal muscle mass
(kg/height (m)2) less than two standard deviations
below the mean of a young reference group(44).
The best way to diagnose sarcopenia is by direct
measurement of lean mass by either DXA or computed
tomography (CT). Although DXA scans produce highly
reproducible and accurate results, they lack the ability
to discriminate among the lean tissue and adipose tissue
sub-compartments. The third lumbar vertebra has been
validated as the standard landmark for body compos-
ition analysis because in this region, skeletal muscle
and adipose tissue correspond to whole body tissue
quantities(45,46). CT image analysis at third lumbar ver-
tebra can distinguish adipose tissue (including visceral,
subcutaneous and intramuscular) from skeletal tissue
(including psoas, paraspinal muscles, transversus
abdominus, external and internal obliques, rectus
abdominus)(45).
Specific tissues are identified based on their anatomical
features and then demarcated and quantified based on
pre-established thresholds of Hounsfield units using com-
mercially available imaging analysis software. CT
Hounsfield unit thresholds used are −29 to 150 for skel-
etal muscle(47), −190 to −30 for subcutaneous and intra-
muscular adipose tissue(47) and −150 to −50 for visceral
adipose tissue(48). Individuals may be compared directly
on this basis of total third lumbar vertebra skeletal mus-
cle cross sectional area (cm2), skeletal muscle index (cm2/
m2) or approximate whole-body tissue masses estimated
from lumbar areas using predetermined regression equa-
tions(45). These regression equations were first developed
for a cancer population using CT scans by Mourtzakis
et al.(45) who converted the cut points developed in a
healthy cohort by DXA(44) from kg/m2 to cm2/m2 using
regression equations. Since then several cut points for
sarcopenia have been published(32,38) and more recently
sex-specific and BMI-specific cut points for sarcopenia
were defined by Martin et al. (<43 cm2/m2 for men
(BMI < 25 cm2/m2), <53 cm2/m2 for overweight/obese
men and <41 cm2/m2 for women)(42).
Despite the presence of increasing prevalence of over-
weight and obesity in cancer patients, sarcopenia is pre-
sent in between 20 and 70 % depending on the tumour
type and sarcopenia definition used. There are over
twenty-five studies in the literature reporting rates of sar-
copenia in different cancer populations but studies are
difficult to compare due to the variety of cut-off points
for sarcopenia that were used. Of these twenty-five stud-
ies, ten used the cut points according to Prado et al.(38)
(38·5 cm2/m2 for females and 52·4 cm2/m2 for males);
five used the Baumgartner cut points(44) which were con-
verted to cm2/m2 using Mourtzakis regression equa-
tions(45) (38·9 cm2/m2 for females and 55·4 cm2/m2 for
males); two used Martin et al.(42) (<43 cm2/m2 for men
(BMI < 25 cm2/m2), <53 cm2/m2 for overweight/obese
men and <41 cm2/m2 for women), and the remainder
used either Fearon et al.(32) (<55 cm2/m2 for men and
<39 cm2/m2 for women) or were based on one muscle
group(37), quartiles of muscle mass(38) or optimal stratifi-
cation analysis(49). Thus, cross-comparison of rates of
sarcopenia across different studies is hampered. Fig. 1
describes the rate of sarcopenia in fifteen different cancer
populations using the most commonly used defini-
tions(38,45). Figures are compared with a reference
healthy population of 378 adults who took part in the
New Mexico Elder Health Survey between 1993 and
1999 and had their body composition measured by
DXA(44). As can be seen in Fig. 1 the majority of the
studies describing sarcopenia in oncology populations
place cancer patients akin to those healthy elderly aged
late 70s to early 80s.
As discussed previously, an additional challenge for
cancer care providers is the fact that sarcopenia is a phe-
nomenon that may be obscured within the bulk of body
weight and body weight change and this is now recog-
nised as a clinically important phenomenon. Fig. 2
depicts several CT scans at lumbar vertebra 3 in cancer
Table 2. Recent large studies highlighting the problem of increased
BMI in cancer patients




Ramos Chaves et al.(40) Variety 450 63
Gioulbasanis et al.(41) Metastatic
primaries
1469 42
Martin et al.(42) GI & Lung 1473 52
Martin et al.(5) variety 8160 40
GI, gastrointestinal.
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patients. It shows the variation (Fig. 2(a)) for four males
with identical amounts of skeletal muscle. Fig. 2(b) high-
lights skeletal muscle variation in three female patients
with identical BMI.
Body composition, sarcopenia and dosing of
chemotherapy
Body composition has emerged as an important predict-
or of anti-cancer drug efficacy and toxicity. Historically
anti-cancer treatment is dosed using body surface area
(BSA) which is calculated using the formula; BSA =
0·007184 × weight0·425 × height0·725. This equation was
published by du Bois and du Bois in 1916; however,
the objective at this time was not to develop a formula
to dose anticancer agents(50,51). It was first introduced
in oncology in order to derive a safe starting dose, and
the use of BSA today as a means to individualise the
dose of chemotherapy has been questioned(42). There is
growing evidence that this approach is invalid(52) as
there can be a 4–10-fold variation in drug clearance
with medications like chemotherapy which have a nar-
row therapeutic index.
Many cytotoxic drugs are largely metabolised and
excreted by the liver and kidney and BSA is not a good
indicator of this function(52). Renal function, if based
on serum creatinine concentration, may be overestimated
in sarcopenic patients which may result in overdosing of
renally excreted drugs, such as carboplatin(53). There is
growing literature to suggest that lean body mass or fat
free mass (FFM), which is mainly composed of skeletal
muscle and metabolic tissues such as liver and kidney(54),
may be a better basis for normalising drug dosages in
cancer patients, especially of hydrophilic drugs(55,56).
Likewise, increased adipose tissue may increase volume
of distribution for highly lipophilic drugs prolonging
their elimination half-lives.
The reason for the increased toxicity may be as a result of
inappropriate dosing of chemotherapy drugs based on BSA,
which has a weak correlation to whole body FFM. Prado
et al.(38) reported that individual variation in FFM could ac-
count for up to three times variation in effective volume of
distribution for chemotherapy administered per unit BSA
in sarcopenic obese patients with solid tumours of the re-
spiratory and gastrointestinal tracts. Thus, administering
the same dose of chemotherapy drug in a patient with low
FFM compared with a patient with normal FFMwould in-
crease the risk of chemotherapy toxicity(38).
The discrepancy between BSA and body composition
has recently been investigated by Stobäus and
co-workers(57) in a cross-sectional study of 630 cancer
patients. They reported a significant discrepancy between
BSA and body composition with more than 30 % of
patients differing considerably from the established
mean of their respective BSA category(57). This implies
that using the BSA in these patients under and over esti-
mates body composition, which in theory leads to an
over and under dose of chemotherapy. The extent of
lean tissue loss in cancer patients varies from individual
to individual and by basing chemotherapy dose on
Fig. 1. (Colour online) Summary of studies reporting sarcopenia in a variety of cancers compared with healthy controls.
For cancer populations sarcopenia defined by computed tomography scan using Prado et al.(38) values of 38·5 cm2/m2
for females and 52·4 cm2/m2 for males; Mourtzakis et al.(45) values of 38·9 cm2/m2 for females and 55·4 cm2/m2 for
males. Reference ranges for healthy population based on appendicular lean mass as assessed by dual-energy X-ray
absorptiometry of <5·45 kg/m2 for females and <7·26 kg/m2 for males.
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BSA the patient may experience increased toxicity par-
ticularly with hydrophilic drugs.
Impact of sarcopenia on tolerance to cytotoxic
chemotherapy
Variability in body composition of cancer patients may
be a source of disparities in the metabolism of cytotoxic
agents. Identification of those with sarcopenia is import-
ant because sarcopenia is associated with elevated tox-
icity to chemotherapy(38,58–62). There is mounting
evidence that sarcopenia increases the risk of toxicity to
many drugs including Epirubicin(58), Capecitabine(63),
Sunitinub(59), Sorafinib(60,61), 5-FU and leucovorin(62).
Table 3 summarises the available evidence for sarcopenia
and dose-limiting toxicity in a variety of cancers and dif-
ferent chemotherapy drugs. Future clinical trials investi-
gating dose reductions in patients with sarcopenia and
dose-escalating studies based on pre-treatment body
composition assessment have the potential to alter cancer
treatment paradigms(64).
In addition to the argument that pharmacokinetic
parameters can explain the higher risk of toxicity in sar-
copenic patients it is also important to note that sarcope-
nic patients are excessively fragile and highly susceptible
to acute medical events that exacerbate
chemotherapy-related toxicity(65). Mechanisms outside
the pharmacokinetic hypothesis linking sarcopenia to
toxicity include metabolic alterations found in cancer
or the role of systemic inflammation. The latter has
been shown to decrease liver cytochrome activities and
drug clearance and may modify drug exposure(66).
Inflammation can also increase the deposition of fat
intramuscularily which then leads to reduced muscle
density. Skeletal muscle density is assessed by analysing
pixel values on CT images with lower density reflecting
fatty muscle infiltration(67). This adds a qualitative di-
mension to the measurement of body composition.
In more recent years, the importance of muscle density
has come to the forefront with much recent research
highlighting its importance in progression-free survival,
treatment response and overall survival. Higher skeletal
muscle density has been associated with improved sur-
vival in renal cell carcinoma(38), melanoma(68) and in a
number of others solid tumours(42). Skeletal muscle dens-
ity could potentially be a more accurate measure of mus-
cle function and therefore precede the development of
sarcopenia. Low skeletal muscle density may be reflective
of patients with a lower performance status.
Sarcopenia and survival
It has been reported that sarcopenia is independently
prognostic of lower survival in obese patients with solid
tumours of the lung and gastrointestinal tract. Prado
et al.(38) reported that patients suffering from sarcopenic
obesity had a shorter survival. The median survival was
reduced in sarcopenic obese patients to 11·3 (95 % CI
7·4, 15·2) months compared with 21·6 (95 % CI 16·9,
26·3) months in non sarcopenic obese patients (P <
0·0001)(38). Sarcopenia has also been identified as a pre-
dictor of overall survival after cytoreductive nephrectomy
for metastatic renal cell carcinoma, following pancreatic
Fig. 2. (Colour online) (a, b) CT scans at lumbar vertebrae 3. Fig. 2(a) shows four male sarcopenic
patients with identical skeletal muscle index (SMI) ranging across different BMI categories. Fig. 2(b)
shows three female patients with identical BMI but varying SMI. Muscle depicted in red in all
images.
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surgery and following curative resection of colorectal
cancer(37,60,69).
Martin et al.(42) showed similar results. This is a study
with a larger sample size of cancer patients (n 1473). The
most striking feature of this analysis is the shorter overall
survival in patients with weight loss, sarcopenia and low
muscle density 8·4 months (95 % CI 6·5, 10·3) compared
with an overall survival of 28·4 months (95 % CI 24·2,
32·6, P< 0·001) in other patients regardless of body
weight(42).
Quality of life
Cancer-associated malnutrition and CC have also been
shown to have profound negative effects on patient’s per-
formance status, psychological well-being and overall
quality of life (QoL)(7,32,35,70). QoL for cancer patients
is a subjective multidimensional construct that represents
the patients psychosocial well-being, functional status,
health perceptions and disease and treatment related
symptoms(71,72).
Due to the advances in oncological practice, which have
resulted in improved morbidity and mortality rates for
patients in recent years(73,74), the relationship between nu-
tritional status and QoL is becoming an important issue in
oncology and almost all newly diagnosed cancer patients
believe that nutrition has a role to play in their anticancer
therapeutic strategy(75). Recent work has suggested that
the complex interplay between metabolic disruption and
pro-inflammatory cytokines in CC often leads to physical,
biochemical and nutritional deterioration which subse-
quently leads to poor QoL(76–78). A recent systematic
review reported a negative correlation between QoL and
weight loss in 23/27 studies of patients with CC(79).
Weight loss has been associated with poor QoL in head
and neck cancer patients as well as in a large cohort of
907 mixed cancer patients(80). It is not surprising that
weight loss has a negative impact on QoL, considering
loss of muscle mass (sarcopenia) is a major cause of fa-
tigue(81,82) and weight loss is associated with reduced func-
tional ability(78). Nutrition-related symptoms associated
with chemotherapy such as nausea, vomiting, fatigue
and constipation negatively impact the patients’ wellbeing,
thus reducing their QoL(83,84). Appetite loss and fatigue,
could be a cause or a consequence of malnutrition in can-
cer patients and lead to subsequent deterioration in global
health status and functional scales, which might result in
dose-limiting toxicities or suspension of chemotherapy
treatment, and ultimately increased morbidity and
mortality(7,64,85,86).
Nutritional care of cancer patients
Unfortunately cachexia has perhaps suffered more from
selective neglect and therapeutic nihilism than any
other symptom requiring palliative care(87). While there
are some new promising drugs undergoing phase III
trials to treat CC at present these are as yet unavailable
outside the research setting. There is currently no consen-
sus on the optimal treatment for CC, yet there is an ur-
gency for improving management. Several trials have
examined single therapies for CC, including oral nutri-
tional supplements, exercise or anti-inflammatory
drugs; however, the results have been disappointing.
Table 3. Summary of studies in various cancers showing toxicity in a variety of chemotherapy drugs according to sarcopenic status




exhibiting toxicity P value
Prado et al.(62) Stage II/III colon cancer 62 5-FU 93 52 0·001
Prado et al.(63) Metastatic breast cancer 55 Capecitabine 50 20 0·039
Prado et al.(58) Stage II/III breast cancer 24 Adjuvant 5-FU, Epirubicin,
cyclophosphamide
55 19 0·03
Antoun et al.(60) Metastatic renal cell
carcinoma
55 Sorafenib 41 13 0·04
Mir et al.(61) Hepatocellular carcinoma 40 Sorafenib 82 31 0·005
Huillard
et al.(106)










55 Sunitinib 77·7 70 NS
Barret et al.(108) Metastatic colorectal
cancer
51 1. Fluoropyrimidine (FP) + oxaliplatin
2. FP + irinotecan
3. FP alone
4. Irinotecan without FP
33·3 13·3 NS
Tan et al.(109) Oesophago-gastric cancer 89 Cisplatin 80 mg/m2, 5-FU 1000 mg/
m2 Epirubicin 50 mg/m2 Cisplatin






31 Imatinib 100 73·7 NS
NS, non-significant; 5-FU, 5-fluorouracil; FP, fluoropyramidine.
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The fundamental difference between the weight loss
observed in CC and that seen in simple starvation is
the lack of reversibility with feeding alone. This seems
to be caused by metabolic changes produced by the tu-
mour, which have a profound effect on the prognosis
of the disease, the symptoms experienced by patients,
and ultimately their survival. Therefore, attempts to
modify the metabolic response to cancer have the poten-
tial to improve both quality and length of life.
For dietitians, traditionally, body weight and BMI have
been used as outcomemeasures, but these measures do not
reflect the body composition changes that may occur dur-
ing chronic diseases such as cancer.Weight loss alone does
not identify the full effect of cachexia on physical func-
tion(78). It is the loss of FFM that is responsible for the
reduced functional status, increased mortality and other
negative outcomes associated with malnutrition. Body
fat is easier to gain than FFM, so studies that show
improved body weight may not translate into reductions
in morbidity or improvements in functional status. To im-
prove functional ability and hence QoL patients need not
only to become weight stable but regain the lean tissue
lost in the cachectic process.
Oral nutritional supplements
Unfortunately for those with established cachexia a
meta-analyses of thirteen randomised controlled trials
have concluded that weight, body composition and func-
tional outcomes fail to improve with oral nutritional sup-
plements alone(88). The clinical characteristic of cachexia
is that it cannot be successfully treated with nutrition
alone as there is partial block to the accretion of lean tis-
sue in cancer patients. The use of anti-inflammatory
agents (either drug agents or nutritional agents such as
EPA) have therefore been advocated in the multi-
pronged approach to care(89,90).
Physical activity
Efforts should be made to encourage physical exercise
(within the capacities of the patient) as a means of pre-
serving and restoring muscle mass and to reduce systemic
inflammation(77). The optimum means of achieving this
is not yet clear but is the subject of major ongoing stud-
ies. Studies targeting cachectic patients have demon-
strated that even in advanced disease peripheral muscle
has the capacity to respond to exercise training(91).
Benefits of exercise include enhancing muscle protein
synthesis, attenuating the catabolic effects of cachexia,
and modulating levels of inflammation. However, there
are challenges and limitations to cachectic patients en-
gaging in exercise and many are not able or willing to
undertake programmes.
Multimodal approaches
As multi-factors are responsible for the development of
cachexia, it has recently been argued that optimal cach-
exia intervention should target all components; multi-
modal therapy for a multidimensional problem(29,92,93).
This multimodal approach would incorporate oral
nutritional supplements, exercise and anti-inflammatory
medications and has been advocated in the prevention
and treatment of CC. Underpinning this approach are
meta-analyses suggesting that each of the interventions
components, while not unequivocally associated with
improved outcome, is more likely than not to be
beneficial(77,88,91,94,95).
The MENAC trial (a multimodal intervention of ex-
ercise, nutrition and anti-inflammatory medication plus
standard care v. standard care alone) to prevent/attenu-
ate cachexia will test the efficacy of a multi-dimensional
approach during chemotherapy. Patients with advanced
lung and inoperable pancreatic cancer about to start
chemotherapy will be randomised to standard care or
standard care plus oral nutritional supplements
enriched with EPA, exercise and non-steroidal anti-
inflammatory drugs. The primary objective is to deter-
mine whether the intervention achieves a difference in
skeletal muscle index at 6 weeks.
Adequate protein alone only slows the loss of muscle
mass. Exercise (both resistance and aerobic) in combination
with adequate energy and protein intake is the key compo-
nent of the prevention and management of sarcopenia.
Preliminary results from the MENAC trials have shown
that cancer patients can gainmusclemass by eating sufficient
protein and engaging in 2 × 30 min walks per week and 3 ×
20 min sessions of stair climbing in their own homes (resist-
ance exercise (KC Fearon et al., unpublished results).
Nutritional targets in cancer patients
We still know very little about the specific nutritional
requirements of cancer patients. In general ranges are
given; for example total daily energy expenditure in
cancer patients is thought to range between 104·6 and
125·52 kJ/kg per d (25 and 30 kcals/kg per d)(96). The op-
timal nitrogen supply for cancer patients cannot be deter-
mined at present and current recommendations are based
on expert opinion and range between a minimum of 1 g/
kg per d and a target supply of 1·2–2 g/kg per d(96–99). As
we have argued, in another article on this subject(100) lean
body mass drives protein requirements, and current
recommended ranges for energy and protein do not
take into account body composition and the likely im-
portant role that varying degrees of wasting or obesity
(or both sarcopenic obesity) have on require-
ments(100,101). Therefore targeted energy and protein
recommendations should be used, so that protein intake
is targeted to protect muscle mass and energy recommen-
dations are calculated according to the overweight or
obesity status(100). For those patients who are obese (be-
tween 17 and 19 % of cancer patients) there are no
specific guidelines as to the energy intake or the target
body weight. It is unclear whether cancer patients experi-
encing obesity related morbidity benefit from mainten-
ance of their heavy body weight or whether some
(limited) degree of weight loss could in some way be de-
sirable. However, separate from energy considerations it
is reasonable to evaluate protein intake and increase it
with the purpose of preventing erosion of lean body
mass(41).
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Levels of malnutrition in 2015 are similar to those
reported >30 years ago, but, today <7 % of cancer
patients have obvious malnutrition (BMI < 18·5 kg/m2).
The majority look normal and 40–60 % are overweight
or obese. However, cachexia and sarcopenia are highly
prevalent across all BMI categories with approximately
one-third of obese cancer patients meeting the criteria
for cachexia and 17–19 % meeting criteria for sarcopenia.
Cachexia and sarcopenia impact significantly on QoL,
tolerance to chemotherapy and ultimately, survival.
Nutrition screening should be mandated in oncology
but it is unclear what tool should be used. Further
research is necessary to identify practical screening
and assessment tools in oncology. At present not all can-
cer patients can avail of one-to-one dietetic care and all
too often they are referred too late in the course of
their disease/cachexia for a meaningful benefit to be
achieved. In an ideal world, nutrition care should begin
in parallel with medical care with weight stabilisation
as an immediate priority, bearing in mind that this
may not be achievable with nutrition alone and
anti-inflammatory agents along with physical activity
are critical in the multimodal approach. Irrespective
of BMI protein intake is of fundamental importance to
slow loss of lean body mass along with physical activity.
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